KROS or ARGX: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
Keros Therapeutics, Inc. - common stock (KROS)
Company Research
Source: Yahoo! Finance
SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits. Keros Therapeutics, Inc. and argenex SE are sporting Zacks Ranks of #1 (Strong Buy) and #3 (Hold), respectively, right now. This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that KROS is likely seeing its earnings outlook improve to a greater extent. However, value investors will care about much more than just this. Value investors are also interested in a number of tried-and-true valuation metrics that help show w
Show less
Read more
Impact Snapshot
Event Time:
KROS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KROS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KROS alerts
High impacting Keros Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
KROS
News
- Keros Therapeutics (NASDAQ:KROS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Zacks.com featured highlights include AES, BorgWarner, Enersys, PG&E and Keros Therapeutics [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics (NASDAQ:KROS) was upgraded by analysts at TD Cowen to a "hold" rating.MarketBeat
- KROS vs. ARGX: Which Stock Is the Better Value Option? [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics (NASDAQ:KROS) had its price target raised by analysts at Bank of America Corporation from $18.00 to $19.00. They now have a "neutral" rating on the stock.MarketBeat
KROS
Earnings
- 11/5/25 - Beat
KROS
Sec Filings
- 1/9/26 - Form 8-K
- 1/9/26 - Form 4
- 12/18/25 - Form 4
- KROS's page on the SEC website